Breakdown | TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 611.42M | 590.82M | 1.00B | 1.12B | 654.71M | 453.74M |
Gross Profit | 279.63M | 269.85M | 593.24M | 659.68M | 376.69M | 189.84M |
EBITDA | 37.19M | 104.06M | 323.46M | 513.25M | 238.36M | 42.16M |
Net Income | 20.98M | 24.19M | 180.84M | 375.31M | 144.45M | -40.37M |
Balance Sheet | ||||||
Total Assets | 1.03B | 1.06B | 1.26B | 1.16B | 612.39M | 427.99M |
Cash, Cash Equivalents and Short-Term Investments | 479.84M | 489.58M | 641.26M | 270.33M | 162.83M | 137.19M |
Total Debt | 132.16M | 146.46M | 182.49M | 188.47M | 67.08M | 102.17M |
Total Liabilities | 258.48M | 289.71M | 455.27M | 416.67M | 202.26M | 168.94M |
Stockholders Equity | 771.37M | 766.67M | 808.22M | 741.95M | 410.13M | 259.05M |
Cash Flow | ||||||
Free Cash Flow | 69.49M | -28.17M | 580.24M | 219.30M | 71.44M | 26.03M |
Operating Cash Flow | 85.25M | 11.34M | 664.26M | 295.81M | 85.49M | 37.50M |
Investing Cash Flow | 201.63M | -47.63M | -335.34M | -203.22M | -4.77M | -18.99M |
Financing Cash Flow | -73.29M | -122.66M | -178.28M | -67.45M | -59.30M | -64.75M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
75 Outperform | HK$384.46M | 8.94 | 5.95% | 11.67% | 0.81% | 27.55% | |
66 Neutral | HK$601.91M | 36.22 | 1.07% | 8.89% | -1.20% | -87.51% | |
64 Neutral | HK$450.00M | 20.55 | 5.02% | 11.11% | -15.22% | -21.37% | |
61 Neutral | HK$201.23M | 8.42 | 10.72% | 5.05% | -22.12% | -28.95% | |
60 Neutral | HK$15.27B | 5.80 | -7.43% | 4.22% | 11.60% | -21.06% | |
58 Neutral | HK$315.03M | 15.01 | 2.73% | 3.46% | -0.69% | ― | |
51 Neutral | HK$149.93M | ― | -18.22% | ― | -56.16% | 62.50% |
Human Health Holdings Ltd. announced a further extension of the term for its investment in a Limited Partnership until June 30, 2026. This decision, made in light of challenging market conditions in the PRC, allows the company to explore better exit options without incurring additional management fees, which is considered beneficial for the company and its shareholders.